Navigation Links
Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg / 500 mg, NDC 0603-3888-20, 60 Count, Lot Numbers T150G10B, T120J10E and T023M10A and Phenobarbital Tablets, USP 32.4 mg, ND

HUNTSVILLE, Ala., Feb. 5, 2011 /PRNewswire/ -- Qualitest Pharmaceuticals today issued a voluntary nationwide recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10mg / 500mg, NDC 0603-3888-20, 60 count, Lot Numbers T150G10B, T120J10E and T023M10A, and Phenobarbital Tablets, USP 32.4 mg, NDC 0603-5166-32, 1000 count, Lot Numbers T150G10B, T120J10E and T023M10A. An individual bottle of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10mg / 500mg, NDC 0603-3888-20, 60 count was found incorrectly labeled with a Phenobarbital Tablets, USP 32.4 mg, NDC 0603-5166-32, 1000 count label, printed with Lot Number T150G10B.  Lots T120J10E and T023M10A used the same stock inventory of labels as Lot T150G10B and are potentially impacted.

As a result of this mix-up patients may unintentionally take Hydrocodone and acetaminophen tablets, instead of the intended dose of Phenobarbital. Unintentional administration of Hydrocodone can lead to serious adverse events including respiratory depression, CNS depression, coma and death, especially in opioid naive patients and patients on other CNS depressants. Unintentional administration of acetaminophen may result in liver toxicity in patients on other acetaminophen containing medications, patients with liver dysfunction, or people who consume more than 3 alcoholic beverages a day. Additionally, missing doses of Phenobarbital could result in loss of seizure control.

No injuries have been reported to date.

Consumers who have affected product should stop using the product and contact Qualitest at 1-800-444-4011 for reimbursement. The lot number can be found on the side of the bottle.

The recall includes the following products:

  • Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10mg / 500mg, NDC 0603-3888-20, 60 count, Lot Numbers T150G10B, T120J10E and T023M10A
  • Phenobarbital Tablets, USP 32.4 mg, NDC 0603-5166-32, 1000 count, Lot Numbers T150G10B, T120J10E and T023M10A

This voluntary recall is being made with the knowledge of the U.S. Food and Drug Administration.

These lots were distributed between Sept. 21, 2010 and Dec. 29, 2010 to wholesale and retail pharmacies nationwide (including Puerto Rico).  Lot numbers can be found on the side of the bottle.  Hydrocodone Bitartrate and Acetaminophen Tablets are large (approximately 16.5 mm in length), pink, capsule-shaped tablets, debossed (3600) on one side, and debossed (V) on the reverse side; Phenobarbital Tablets are small (approximately 6.4 mm in diameter), white, round, biconvex, scored tablets, debossed (5012) and (V) on one side and plain on the reverse side. All patients who have filled prescriptions of Phenobarbitol manufactured by Qualitest, are asked to double check the identity of their tablets.

Qualitest is notifying all customers who may have received affected product and arranging for the return of any affected product.

Consumers with questions may contact Qualitest at 1-800-444-4011 for more information.

Adverse reactions or quality problems experienced with the use of this product may be reported to the manufacturer or to FDA's MedWatch Adverse Event Reporting program either on line, by regular mail, or by fax.

Mail to MedWatch 5600 Fishers Lane, Rockville, MD 20852-9787

  • Fax: 1-800-FDA-0178

About Qualitest

Founded in 1983, Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a current portfolio exceeding 600 products, the company has grown significantly since its inception and is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is a wholly owned subsidiary of Endo Pharmaceuticals (Nasdaq: ENDP), a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics (  

SOURCE Qualitest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Qualitest Pharmaceuticals Selects TrackWise® for Comprehensive Enterprise Quality and Document Management
2. Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
3. Lotus Pharmaceuticals to Expand Construction of Beijing Facility
4. Quercegen Pharmaceuticals LLC Obtains FDA GRAS Notified Status for its QU995™ Quercetin with Purity Greater than 99.5%
5. Onyx Pharmaceuticals Appoints Bill Ringo to Board of Directors
6. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
7. Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering
8. Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B
9. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
10. Dr. Peter Thompson Joins Anthera Pharmaceuticals Board of Directors
11. Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives
Post Your Comments:
(Date:10/12/2015)... Apheresis is an invasive process that involves ... other components from whole blood. In this procedure, the blood ... apheresis machine or a blood cell separator. The apheresis equipment ... blood components. A selected part of the blood is removed, ... the patient. It involves the use of devices and disposables ...
(Date:10/12/2015)... Corporation (NASDAQ: LMNX ) today announced that it expects ... 2015 on Monday, November 2, 2015. A press release announcing ... trading. --> --> ... highlights and financial results for the third quarter ended September ... time. . Simply log on to ...
(Date:10/12/2015)... 2015 This study focuses on China,s ... the two past decades, the industry has been growing at ... and rising consumer consumptions in China ... China is one of the world,s ... economies in the world, China is ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 2015 , ... According to an ESPN report published on October ... accidentally elbowed him in the left eye during the first day of practice for ... a series of setbacks, including a knee injury that has interfered with his ability ...
(Date:10/13/2015)... Irving, TX (PRWEB) , ... October 13, 2015 ... ... has tapped Dr. Bill Saye as the newest professional to introduce the latest ... Saye is highly recognized as a leading professional in Obstetrics and Gynecology and ...
(Date:10/13/2015)... ... October 13, 2015 , ... CVS/pharmacy, the retail division of ... enrolling and serving insurance consumers who do not have a bank account, which ... premiums. In “Health Plan Engagement Strategies: The ABCs of Serving Consumers Who Don’t ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... smoke-free communities, and the Florida Apartment Association (FAA) has partnered with the Florida ... communities meet the demand. , The FAA Smoke-Free Multifamily Housing Program launched ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Just under ... would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all of their ... success, and within weeks the company was flooded with phone calls from interested buyers. ...
Breaking Medicine News(10 mins):